In the last few years, there has been an increase in research around using psychedelic drugs, like LSD and magic mushrooms, as treatments for mental health conditions. And recently, two Canadian companies working in the sphere have gotten a special designation from a big U.S. regulator that could fast-track the development and review of their drugs.
Sean Silcoff is a journalist with The Globe’s Report on Business. He has been looking at recent developments in these companies and how that fits into the bigger picture of investor excitement around these drugs.
Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com
How seafood from North Korean forced labour ends up in Canada
The deadly challenges of getting aid into Gaza
School boards take on social media giants
Canada’s uncertain AI future
Four reasons why you can’t afford housing
What to know about the upcoming total solar eclipse
How sleep affects our brains
Amid a housing crisis, students build tiny homes for teachers
What you need to know about your CPP money
Why single parents are struggling in Canada
The political fight over the carbon tax
Who’s left to oppose Vladimir Putin?
Why full parole was granted to a multiple murderer
The dark side of Bay Street’s hottest finance funds
The challenge with preparing for wildfires in B.C.
Why millennial women are so burnt out
Where Haiti could go from here
The ‘invisible’ opioid crisis in small towns
The debate around using hormone therapy for menopause
Create your
podcast in
minutes
It is Free
Front Burner
At Issue
The Daily
Today, Explained
Morning Wire